Introduction: Prognostic classifications for patients treated with sorafenib for hepatocellular carcinoma (HCC) facilitate stratification in trials and inform clinical decision making. Recently, 3 different prognostic models (hepatoma arterial-embolization prognosis [HAP] score, sorafenib advanced HCC prognosis [SAP] score, and Prediction Of Survival in Advanced Sorafenib-treated HCC [PROSASH]-II) have been proposed specifically for patients treated with sorafenib. This study aimed to compare the prognostic performance of different scores. Methods: We analyzed a large prospective database gathering data of 552 patients treated with sorafenib from 7 Italian centers. The performance of the HAP, SAP, and PROSASH-II models were compared with those of generic HCC prognostic models (including the Barcelona Clinic for Liver Cancer and Italian Liver Cancer staging systems, albumin-bilirubin grade, and Child-Pugh score) to verify whether they could provide additional information. Results: The PROSASH-II model improved discrimination (C-index 0.62) compared with existing prognostic scores (C-index ≤0.59). Its stratification significantly discriminated patients, with a median overall survival of 21.5, 15.3, 9.3, and 6.0 months for risk group 1, 2, 3, and 4, respectively. The HAP and SAP score were also validated but with a poorer performance compared with the PROSASH-II. Discussion: Although suboptimal, PROSASH-II is the most effective prognostic classification model among other available scores in a large Italian population of patients treated with sorafenib.

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib / Vito Sansone; Francesco Tovoli; Andrea Casadei-Gardini; Giovan Giuseppe Di Costanzo; Giulia Magini; Rodolfo Sacco; Tiziana Pressiani; Franco Trevisani; Margherita Rimini; Raffaella Tortora; Elena Nardi; Luca Ielasi; Fabio Piscaglia; Alessandro Granito. - In: CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY. - ISSN 2155-384X. - ELETTRONICO. - 12:1(2021), pp. e00286.1-e00286.7. [10.14309/ctg.0000000000000286]

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib

Vito Sansone
;
Francesco Tovoli;Franco Trevisani;Elena Nardi;Luca Ielasi;Fabio Piscaglia;Alessandro Granito
2021

Abstract

Introduction: Prognostic classifications for patients treated with sorafenib for hepatocellular carcinoma (HCC) facilitate stratification in trials and inform clinical decision making. Recently, 3 different prognostic models (hepatoma arterial-embolization prognosis [HAP] score, sorafenib advanced HCC prognosis [SAP] score, and Prediction Of Survival in Advanced Sorafenib-treated HCC [PROSASH]-II) have been proposed specifically for patients treated with sorafenib. This study aimed to compare the prognostic performance of different scores. Methods: We analyzed a large prospective database gathering data of 552 patients treated with sorafenib from 7 Italian centers. The performance of the HAP, SAP, and PROSASH-II models were compared with those of generic HCC prognostic models (including the Barcelona Clinic for Liver Cancer and Italian Liver Cancer staging systems, albumin-bilirubin grade, and Child-Pugh score) to verify whether they could provide additional information. Results: The PROSASH-II model improved discrimination (C-index 0.62) compared with existing prognostic scores (C-index ≤0.59). Its stratification significantly discriminated patients, with a median overall survival of 21.5, 15.3, 9.3, and 6.0 months for risk group 1, 2, 3, and 4, respectively. The HAP and SAP score were also validated but with a poorer performance compared with the PROSASH-II. Discussion: Although suboptimal, PROSASH-II is the most effective prognostic classification model among other available scores in a large Italian population of patients treated with sorafenib.
2021
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib / Vito Sansone; Francesco Tovoli; Andrea Casadei-Gardini; Giovan Giuseppe Di Costanzo; Giulia Magini; Rodolfo Sacco; Tiziana Pressiani; Franco Trevisani; Margherita Rimini; Raffaella Tortora; Elena Nardi; Luca Ielasi; Fabio Piscaglia; Alessandro Granito. - In: CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY. - ISSN 2155-384X. - ELETTRONICO. - 12:1(2021), pp. e00286.1-e00286.7. [10.14309/ctg.0000000000000286]
Vito Sansone; Francesco Tovoli; Andrea Casadei-Gardini; Giovan Giuseppe Di Costanzo; Giulia Magini; Rodolfo Sacco; Tiziana Pressiani; Franco Trevisani; Margherita Rimini; Raffaella Tortora; Elena Nardi; Luca Ielasi; Fabio Piscaglia; Alessandro Granito
File in questo prodotto:
File Dimensione Formato  
Comparison of Prognostic Scores.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 353.36 kB
Formato Adobe PDF
353.36 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/806237
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact